BofA Securities initiated coverage on Viridian Therapeutics with a new price target

Nov 19, 2026
bofa-securities-initiated-coverage-on-viridian-therapeutics-with-a-new-price-target

BofA Securities initiated coverage of Viridian Therapeutics with a rating of Buy and set a new price target of $47.00 Real-time VRDN news, filings and…

Leave a comment